Results 61 to 70 of about 939 (187)

Safety and tolerability of ubrogepant following intermittent, high-frequency dosing:Randomized, placebo-controlled trial in healthy adults

, 2019
Background: Ubrogepant is a novel, oral calcitonin gene–related peptide (CGRP) receptor antagonist in development for the acute treatment of migraine.
Ayele, Girma, Jakate, Abhijeet, Miceli, Rosa, Szegedi, Armin, Trugman, Joel M., Goadsby, Peter J.; id_orcid, Finnegan, Michelle, Watkins, Paul B., Tepper, Stewart J., Severt, Lawrence, Butler, Matthew   +10 more
core   +1 more source

Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine

Medicine in Drug Discovery, 2020
Purpose: Current acute migraine treatment consists of migraine-specific agents, namely triptans, as well as non-specific analgesia, such as non-steroidal anti-inflammatory drugs and acetaminophen (paracetamol).
David Moreno-Ajona, Abigail Pérez-Rodríguez, Peter J. Goadsby   +2 more
doaj   +1 more source

A Comprehensive Review of the Mechanism, Efficacy, Safety, and Tolerability of Ubrogepant in the Treatment of Migraine

Cureus, 2023
Ubrogepant is an innovative medication designed for the acute treatment of migraine, a debilitating neurological condition that profoundly impairs quality of life, productivity, and social interactions. This comprehensive review assesses the efficacy, safety, tolerability, and mechanism of action of ubrogepant through a rigorous methodology, including ...
Dighriri, Ibrahim M, Nazel, Shahad, Alharthi, Aeshah M, Altowairqi, Nasreen A, Albariqi, Aqeel M, Tohari, Mona A, Alameer, Atheer A, Alsaran, Amjad K, ALshammari, Fares R, AlMutairi, Naif F, Alsubaie, Fahad M, Alharbi, Turki A   +11 more
openaire   +2 more sources

Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment

Clinical and Translational Science, 2020
Ubrogepant (MK‐1602) is a novel, oral, calcitonin gene‐related peptide receptor antagonist in clinical development with positive phase III outcomes for acute treatment of migraine.
Chi‐Chung Li, Tiffini Voss, Ken Kowalski, Bei Yang, Huub Jan Kleijn, Christopher J. Jones, Rolien Bosch, David Michelson, Matthew DeAngelis, Yang Xu, Iris Xie, Prajakti A. Kothare   +11 more
doaj   +1 more source

Real‐world diagnosis and treatment of individuals with migraine in the United States: The Migraine Insights in Diagnosis and Treatment (MIND) study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The objective of this study was to describe the real‐world diagnosis and treatment patterns of individuals newly diagnosed with migraine in the United States (US). Background Over 10% of adults in the US are living with migraine.
Fred Cohen, Vincent Martin, Avani Patel, Shelby L. Corman, Katie B. Tellor, Meghan Fajardo, D. Cortney Hayflinger, Simon Dagenais   +7 more
wiley   +1 more source

Repurposing of Existing Pharmaceutical Drugs Against Monkey-pox Virus: An In Silico Study

, 2022
Monkeypox virus (MPXV) is considered as zoonotic disease with characteristics comparable to smallpox virus. The disease is now a global epidemic concern. Currently, tecovirimat is approved by US Food and Drug Administration (FDA) for MPXV treatment.
Kaushik Sarkar (3203289), Rajesh Kumar Das (14299053)   +1 more
core   +1 more source

In Silico Clinical Trials in Drug Development: Virtual Patients, Applications, and Regulatory Convergence

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1181-1194, November 2026.
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus, Sheng‐Ya Wang, Edward W. G. Ashton, Rosie K. Barrows, Molly Monks, Yuzhang Ge, Arthur Lefebvre, Steven A. Niederer   +7 more
wiley   +1 more source

Retrospective analysis of the tolerability and effectiveness of rimegepant for the acute treatment of migraine in adolescents. [PDF]

Headache
Abstract Objective This study aims to evaluate the tolerability and effectiveness of the off‐label use of rimegepant as acute migraine treatment in adolescents. Background Calcitonin gene‐related peptide (CGRP) levels are elevated during migraine attacks.
Tourlas K, Ilangovan S, White C, Irwin SL, Pavitt S.   +4 more
europepmc   +2 more sources

2‐Chloro‐5‐(trifluoromethyl)aniline‐Derived Schiff Base Palladium(II) Complexes: From Molecular Design to Acute Toxicity Assessment

ChemistryOpen, Volume 15, Issue 10, October 2026.
Four new Schiff bases derived from 2‐chloro‐5‐(trifluoromethyl)aniline and their corresponding palladium(II) complexes were obtained and analyzed by multiple spectroscopic techniques. Single‐crystal X‐ray diffraction elucidated the structures of all the ligands and complexes 2 and 4. Their toxicity was assessed on Triticum aestivum L.
Andreea Elena Ştefan, Cristina Elena Dinu‐Pîrvu, Sergiu Shova, Ştefania Felicia Bărbuceanu, Teodora Venera Apostol, Diana Carolina Ilieş, Mihaela Badea, Mihaela Dinu, Robert Viorel Ancuceanu, Doina Drăgănescu, Elena Pahonţu   +10 more
wiley   +1 more source

Gepants for abortive treatment of migraine: A network meta‐analysis

Brain and Behavior, 2020
Objectives To evaluate and compare the efficacy and safety of gepants for abortive treatment of migraine by network meta‐analysis. Materials & Methods Publications, which were randomized controlled trials (RCTs) about gepants for abortive treatment of ...
Peiwei Hong, Tianlin Tan, Yao Liu, Jing Xiao   +3 more
doaj   +1 more source